Search results for " Hepatitis C."

showing 10 items of 174 documents

An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C.

2014

none 29 no Background: Aim was to select naïve patients with genotype 1 chronic hepatitis C having a high probability of response to Peg-interferon. +. ribavirin therapy. Methods: In 1073 patients (derivation cohort), predictors of rapid and sustained virological response were identified by logistic analysis; regression coefficients were used to generate prediction models for sustained virological response. Probabilities at baseline and treatment week 4 were utilized to develop a decision rule to select patients with high likelihood of response. The model was then validated in 423 patients (validation cohort). Results: In the derivation cohort, 257 achieved rapid virological response and 8…

OncologyMaleHepacivirusPredictive Value of Testchronic hepatitis C; prediction model of response; peginterferon plus ribavirin dual therapyHepacivirusPolyethylene GlycolPolyethylene Glycolschemistry.chemical_compoundGenotypeViralChronicRapid virological responseDrug CarrierChronic hepatitisSettore MED/12 - GastroenterologiaDrug CarriersbiologyGastroenterologyRecombinant ProteinMiddle AgedViral LoadPrognosisHepatitis CRecombinant ProteinsHCV infectionTreatment OutcomePredictive value of testsCombinationRNA ViralDrug Therapy CombinationFemaleChronic hepatitis; HCV infection; Peg-interferon and ribavirin treatment; Predictors of sustained virological response rapid virological response; Adult; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prognosis; RNA Viral; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Hepatology; GastroenterologyViral loadHumanAdultmedicine.medical_specialtyGenotypePrognosiAlpha interferonPredictors of sustained virological response rapid virological responseReal-Time Polymerase Chain ReactionAntiviral AgentsDrug TherapyPredictive Value of TestsInternal medicinePredictors of sustained virological responseLinear regressionRibavirinmedicinechronic hepatitis CHumansAntiviral AgentHCV infection; Predictors of sustained virological response Rapid virological response; Peg-interferon and ribavirin treatment; Chronic hepatitisHepaciviruHepatologybusiness.industryRibavirinInterferon-alphaHepatologyHepatitis C Chronicbiology.organism_classificationchemistryImmunologyChronic hepatitiRNAprediction model of responsepeginterferon plus ribavirin dual therapybusinessPeg-interferon and ribavirin treatmentDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib

2021

Background Hepatocellular carcinoma (HCC) treatment remains a big challenge in the field of oncology. The liver disease (viral or not viral) underlying HCC turned out to be crucial in determining the biologic behavior of the tumor, including its response to treatment. The aim of this analysis was to investigate the role of the etiology of the underlying liver disease in survival outcomes. Patients and methods We conducted a multicenter retrospective study on a large cohort of patients treated with lenvatinib as first-line therapy for advanced HCC from both Eastern and Western institutions. Univariate and multivariate analyses were performed. Results Among the 1232 lenvatinib-treated HCC pat…

OncologyPhenylurea CompoundatezolizumabCancer Researchmedicine.medical_specialtyCarcinoma HepatocellularQuinolinelenvatinibbevacizumabchemistry.chemical_compoundLiver diseaseRetrospective StudieNon-alcoholic Fatty Liver DiseaseInternal medicineMedicineHumansnonalcoholic steatohepatitisOriginal ResearchRetrospective StudiesUnivariate analysisSettore MED/12 - GastroenterologiaPerformance statusbusiness.industryPhenylurea CompoundsHazard ratioLiver NeoplasmsRetrospective cohort studyHepatitis Chepatocellular carcinomamedicine.diseasePrognosisdigestive system diseasesadvanced hepatocarcinoma; atezolizumab; bevacizumab; hepatitis C; hepatocellular carcinoma; immunotherapy; lenvatinib; nonalcoholic steatohepatitis; sorafenibadvanced hepatocarcinomaOncologychemistryLiver NeoplasmHepatocellular carcinomanonalcoholic steatohepatitiQuinolinessorafenibimmunotherapyhepatitis CbusinessLenvatinibHuman
researchProduct

The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach.

2004

Hepatitis C virus chronic infection is currently the most common cause of end-stage liver disease. The benefit of antiviral therapy on liver histology and its impact on the long-term course of the disease has been extensively studied. However, the results are still equivocal and the overall assessment of treatment effect remains difficult to evaluate. Although the conclusions of the last National Institute of Health Consensus Development Conferences on Hepatitis C have recently been published, several important issues still remain unanswered. We review the available data by an evidence-based approach and conclude that: 1) peginterferon alfa is more effective than conventional interferon in …

Oncologymedicine.medical_specialtyCirrhosisCarcinoma HepatocellularHepatitis C virusDiseasemedicine.disease_causeAntiviral AgentsLiver diseasechemistry.chemical_compoundMaintenance therapyPegylated interferonInternal medicineDrug DiscoverymedicineHumansViral hepatitis CRandomized Controlled Trials as TopicPharmacologyEvidence-Based Medicinebusiness.industryRibavirinLiver NeoplasmsHistological benefitHepatitis CHepatitis C Chronicmedicine.diseaseLong-term outcomeTreatment OutcomechemistryCombination treatmentImmunologybusinessPegylated interferonmedicine.drugCurrent pharmaceutical design
researchProduct

Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort

2018

Background and aims: Large scale, real life data on the long term course of liver disease after HCV clearance obtained with DAAs are still scanty, and the separate effects on hepatic and non-hepatic causes of death still unclear. Method: We evaluated 4147 patients (mean age: 65.7 ± 11.5 years, 57.6% males) included in the prospective RESIST-HCV cohort who started DAAs treatment in 22 centres between March 2015 and April 2017. All patients were follow after SVR to register liver-related and unrelated outcomes. The primary endpoint was the evaluation of survival since starting DAAs. Cox regression analysis was used to assess the predictors of liver-related and unrelated death. Results: Patien…

Oncologymedicine.medical_specialtyDAA disease outcome hepatitis CHepatologybusiness.industryDisease outcomeGastroenterology02 engineering and technology021001 nanoscience & nanotechnology03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisInternal medicineCohortMedicine030211 gastroenterology & hepatology0210 nano-technologybusiness
researchProduct

Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association…

2013

AbstractThe first-generation Protease Inhibitors Boceprevir and Telaprevir administered in triple therapy regimens with Peg-interferon alpha and Ribavirin have been proven effective in increasing the rate of Sustained Virological Response in both naive and treatment-experienced patients with chronic genotype-1 hepatitis C. However, at the individual level, the therapeutic advantage of triple therapy is highly variable and results from the combination of multiple factors related to the characteristics of patient, viral status and liver disease.The recommendations presented are promoted by the Italian Association for the Study of the Liver, with the aim to help the physician in the decision-m…

Oncologymedicine.medical_specialtyProlinePegylated-interferonAlpha interferonHepacivirusPharmacologyAntiviral AgentsTelaprevirTelaprevirPolyethylene GlycolsHCV THERAPYchemistry.chemical_compoundLiver diseaseDrug TherapyPegylated interferonBoceprevirInternal medicineRibavirinmedicineHumansProtease InhibitorsChronicBoceprevir; Cirrhosis; Hepatitis C; Pegylated-interferon; Ribavirin; Telaprevir; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Ribavirin; Gastroenterology; HepatologyBoceprevirDrug CarriersHepatologybusiness.industryRibavirinGastroenterologyInterferon-alphaHepatitis CHepatologyHepatitis C Chronicmedicine.diseaseHepatitis CCirrhosischemistryCombinationDrug Therapy CombinationbusinessOligopeptidesmedicine.drug
researchProduct

The road map toward an hepatitis C virus-free transplant population

2018

Antiviral therapy to eradicate hepatitis C virus (HCV) infection improves outcomes in patients undergoing liver transplantation (LT) for advanced chronic HCV with or without hepatocellular carcinoma. Traditionally, antiviral therapy focused on the use of interferon (IFN)-based regimens, with antiviral treatment initiated in the posttransplant period once recurrent HCV disease with fibrosis in the allograft was identified. The use of IFN-based therapy was limited in pretransplant patients with advanced liver disease. Earlier intervention, either before transplantation or early after LT, is now feasible with the advent of second-generation direct-acting antiviral agents (DAAs) with superior t…

Oncologymedicine.medical_specialtymedicine.medical_treatmentHepatitis C virusinfectious diseasePopulationHepacivirus030230 surgeryLiver transplantationmedicine.disease_causeclinical research/practiceinfection and infectious agents—viral: hepatitis CAntiviral Agents03 medical and health sciencesLiver diseasePostoperative Complications0302 clinical medicineeditorial/personal viewpointInternal medicinemedicineHumansImmunology and Allergyliver disease: infectiousPharmacology (medical)educationclinical research/practice; editorial/personal viewpoint; infection and infectious agents—viral: hepatitis C; infectious disease; liver disease: infectious; liver transplantation/hepatology; Immunology and Allergy; Transplantation; Pharmacology (medical)education.field_of_studyTransplantationbusiness.industrymedicine.diseaseHepatitis CLiver TransplantationTransplantationClinical trialhepatitis C infectious disease liver disease: infectious liver transplantation/hepatology [clinical research/practice editorial/personal viewpoint infection and infectious agents-viral]TolerabilityHepatocellular carcinoma030211 gastroenterology & hepatologybusinessliver transplantation/hepatology
researchProduct

Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling…

2017

Background Hepatitis C virus (HCV) is a leading cause of liver-related morbidity and mortality worldwide. In the European Union (EU), treatment and cure of HCV with direct-acting antiviral therapies began in 2014. WHO targets are to achieve a 65% reduction in liver-related deaths, a 90% reduction of new viral hepatitis infections, and 90% of patients with viral hepatitis infections being diagnosed by 2030. This study assessed the prevalence of HCV in the EU and the level of intervention required to achieve WHO targets for HCV elimination. Methods We populated country Markov models for the 28 EU countries through a literature search of PubMed and Embase between Jan 1, 2000, and March 31, 201…

Pediatricsddc:616.07medicine.disease_cause0302 clinical medicineCost of IllnessEpidemiologyPrevalenceEPIDEMIOLOGY030212 general & internal medicineSettore SECS-P/01 - Economia PoliticaCIRRHOSISmedia_commonddc:616Antiviral Agents/therapeutic useeducation.field_of_studyINJECT DRUGSGastroenterologyHCV INFECTIONvirus diseasesHepatitis CEmigration and ImmigrationDISEASE BURDENHepatitis CMarkov ChainsEmigration and Immigration/statistics & numerical data030211 gastroenterology & hepatologyViral hepatitisModelling ; Eradication ; European Union ; Hepatitis C ; prevalenceCOUNTRIESmedicine.medical_specialtyHepatitis C virusPopulationUNITED-STATESWorld Health OrganizationAntiviral Agents03 medical and health sciencesSDG 3 - Good Health and Well-beingPEOPLEInternal medicineIntervention (counseling)medicineJournal Articlemedia_common.cataloged_instanceHumansEuropean UnionViremiaEuropean unionDisease EradicationeducationHepatitis C/diagnosis/drug therapy/epidemiology/prevention & controlHepatologybusiness.industryViremia/diagnosis/drug therapy/epidemiology/prevention & controlHepatologymedicine.diseaseVirologyPREVENTIONdigestive system diseasesHuman medicineVIRAL-HEPATITISbusinessLancet Gastroenterology & Hepatology
researchProduct

Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency

2014

a b s t r a c t Background: Data on the efficacy of Peg-interferon/ribavirin therapy for chronic hepatitis C are mostly derived from treatment of selected patients enrolled in clinical trials. This study aimed to assess the effectiveness of Peg-interferon/ribavirin therapy in “real world” chronic hepatitis C patients in Italy. Methods: Independent observational multicentre study including consecutive patients receiving Peginterferon/ribavirin in the 18 months before (retrospective phase) and after (prospective phase) the start of the study. Results: 4176 patients were eligible. The final study population consisted of 2051 patients in the retrospective and 2073 in the prospective phase. Sust…

RegistrieMaleCirrhosismedicine.disease_causePolyethylene GlycolGastroenterologyPolyethylene Glycolschemistry.chemical_compoundHepatitis VirusesHepatitis ViruseProspective StudiesViralRegistriesChronicProspective cohort studyDrug CarrierDrug CarriersSettore MED/12 - GastroenterologiaMedicine (all)GastroenterologyRecombinant ProteinMiddle AgedHepatitis CRecombinant ProteinsTreatment OutcomeItalyCombinationRNA ViralPopulation studyDrug Therapy CombinationFemaleHumanmedicine.medical_specialtyGenotypeHepatitis C virusAlpha interferonRibavirin; Sustained virological response (SVR); TreatmentAntiviral AgentsFollow-Up StudieRibavirin; Sustained virological response (SVR); Treatment; Hepatology; GastroenterologyDrug TherapyInternal medicineRibavirinmedicineHumansAntiviral AgentHepatologybusiness.industryRibavirinInterferon-alphaHCV therapyHepatitis C ChronicHepatologymedicine.diseaseClinical trialTreatmentProspective StudiechemistryImmunologyRNARibavirin; Sustained virological response (SVR); Treatment; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Female; Follow-Up Studies; Genotype; Hepatitis C Chronic; Hepatitis Viruses; Humans; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; RNA Viral; Recombinant Proteins; Ribavirin; Treatment Outcome; RegistriesbusinessRibavirin; Sustained virological response (SVR); Treatment; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Female; Follow-Up Studies; Genotype; Hepatitis C Chronic; Hepatitis Viruses; Humans; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; RNA Viral; Recombinant Proteins; Ribavirin; Treatment Outcome; Registries; Gastroenterology; Hepatology; Medicine (all)Follow-Up StudiesSustained virological response (SVR)
researchProduct

[Access to hepatitis C treatment: a lesson for the future.]

2018

L’immissione in commercio dei farmaci antivirali ad azione diretta (DAA) di nuova generazione per la terapia dell’infezione cronica da virus dell’epatite C ha rivoluzionato lo scenario precedente e ha messo a dura prova le istituzioni, a causa del prezzo elevato delle terapie. Un’analisi di quanto accaduto negli ultimi tre anni, specialmente in Italia, ci aiuta a comprendere come è stata gestita la contrattazione dei prezzi e soprattutto con quali criteri si è scelto, in una prima fase, di consentire un accesso ristretto in base al bisogno di cura dei pazienti. Ciò consente di mettere a fuoco alcuni temi importanti e di individuare le sfide che ci attendono nel prossimo futuro. The new gene…

Settore MED/02 - Storia Della MedicinaBioethics Hepatitis C Access policies Ethics HCV High price innovative drugs Access to treatment Direct Acting Antivirals Equity ScreeningItalyBioetica Epatite C Politiche di accesso Etica HCV Farmaci innovativi ad alto costo Accesso alle terapie Direct Acting Antivirals Equità ScreeningHumansHepatitis C ChronicAntiviral AgentsDrug CostsHealth Services AccessibilityRecenti progressi in medicina
researchProduct

Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C

2013

We assessed the cost-effectiveness of sofosbuvir (SOF)-based triple therapy (TT) compared with boceprevir (BOC)- and telaprevir (TVR)-based TT in untreated genotype 1 (G1) chronic hepatitis C (CHC) patients discriminated according to IL28B genotype, severity of liver fibrosis, and G1 subtype. The available published literature provided the data source. The target population was made up of untreated Caucasian patients, aged 50 years, with G1CHC and these were evaluated over a lifetime horizon by Markov model. The study was carried out from the perspective of the Italian National Health Service. Outcomes included discounted costs (in euros at 2013 value), life-years gained (LYG), quality-adju…

Settore MED/12 - Gastroenterologiamedicine.medical_specialtyCirrhosisHepatologySofosbuvirCost effectivenessbusiness.industryGastroenterologyPharmacologyHepatologycost-effectiveness sofosbuvir boceprevir telaprevir chronic hepatitis Cmedicine.diseaseTelaprevirchemistry.chemical_compoundchemistryTolerabilityBoceprevirInternal medicineGenotypemedicineSettore SECS-S/05 - Statistica SocialeSettore SECS-S/01 - Statisticabusinesshealth care economics and organizationsmedicine.drugDigestive and Liver Disease
researchProduct